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REPLY
We greatly appreciate the comments of our colleagues and
recognize that the issue of genetic testing is controversial
both in pediatric cardiology and other fields of medicine.
We believe that in the case of the 22q11 deletion, the
controversy centers on two issues: 1) the utility of early
screening and diagnosis, and 2) the ability to identify by clinical
exam alone those patients at risk for having a 22q11 deletion.
It is clinically important to identity the patient with the
22q11 deletion in infancy for several reasons. First, the
infant recognized to have the deletion is at risk for multiple
extracardiac anomalies that warrant early detection and
intervention. These include palatal abnormalities, feeding
disorders, hypocalcemia, immune deficiencies, renal anom-
alies, and speech and learning disabilities (1,2). Many of
these abnormalities are not apparent on examination alone
but are only identified by specialized tests. Although all
patients with congenital heart disease should be examined
carefully for noncardiac features, infants with a 22q11
deletion are at risk for known anomalies that are best
managed by early identification and intervention.
It is also important to identify the infant with a 22q11
deletion for family counseling purposes. Approximately 8%
to 28% of cases are familial in origin. Most affected parents
are not diagnosed as deletion positive until their child is
diagnosed (2,3). The parent with a deletion carries a 50%
chance of passing the deletion-bearing chromosome to
additional offspring. Although one cannot predict the out-
come for the fetus that inherits the deletion bearing chro-
mosome, appropriate monitoring and counseling can be
offered to the family because many affected infants have severe
forms of heart disease that carry significant morbidity and
mortality (1,2). Thus, screening neonates with specific cardiac
defects for a 22q11 deletion assures that familial cases will be
identified and that appropriate counseling will be offered.
A separate controversy concerns the ability to diagnose
the 22q11 deletion syndrome clinically at birth. We agree
that subtle dysmorphic features in patients with a 22q11
deletion can often eventually be recognized, particularly in
the school-age child. Therefore, in the conclusion of our
paper, we recommend testing for a 22q11 deletion in the
school-age child with a conotruncal defect only in the
presence of additional syndromic features.
However, our experience and published experience dem-
onstrates that subtle clinical features of the 22q11 deletion
syndrome may not be apparent in infancy, when we believe
the diagnosis should ideally be made. For example, Dr.
Digilio and her colleagues report five infants whom they had
initially considered to have isolated cardiac defects until
reexamination showed otherwise (4). In two of their cases,
syndromic features were not recognized until after the
deletion was detected and the infants reexamined (5).
Therefore, even experienced dysmorphologists can “over-
look” subtle syndromic features in the infant.
Given the high frequency of 22q11 deletions in patients
with interrupted aortic arch type B, truncus arteriosus and
tetralogy of Fallot (TOF) with additional aortic arch or
vessel anomalies, routine testing would seem to be less
controversial in this cohort of infants (6). The question
remains whether testing the infant with TOF and a normal
left aortic arch is necessary or can be clinically determined.
Additional studies are likely to answer this question more
precisely. However, since identification of the syndromic
infant is likely to depend upon the experience of the
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examiner, and because laboratory screening may prove to be
less expensive than repeated examination by medical spe-
cialists (particularly as less expensive PCR based screening
assays are put to clinical use) (7), we believe that routine
testing of this population can also be justified.
Testing in infancy can avoid the frustration that families
often experience as they try to understand why the cardiac
defect occurred, whether it will recur in subsequent preg-
nancies and whether other clinical problems, such as feeding
disorders, relate to the cardiac disease. The 22q11 deletion
syndrome provides parents with a unifying diagnosis and
can preempt visits to different sub-specialists in search of
new diagnoses. Most importantly, we hope that this discus-
sion will heighten physicians’ awareness of the 22q11
deletion syndrome. Until more conclusive cost benefit analyses
and clinical studies can better define appropriate screening
guidelines, the decision to test for a 22q11 deletion in the
cardiac patient must be considered by each physician according
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Role of Nitric Oxide in
Venous and Arterial Graft Failure
We read with interest the paper from Chello et al. (1)
reporting greater neutrophil adhesion in segments of human
saphenous vein (SV) than internal mammary artery (IMA),
which they ascribed to different endothelial nitric oxide
(NO) formation in the two vessels. This, according to the
authors, explains the superior early and long-term patency
of the IMA as a conduit for coronary artery bypass surgery
(CABG) when compared with the SV. Although we agree
that the IMA is a preferable conduit, and that the SV
produces less endothelial NO than arteries (2), we have a
number of concerns over the methodology as well as the
clinical implications of this study.
First, the authors presented no data as to the amount of
endothelium present in the SV or IMA segments investi-
gated. In our experience, this can be very variable and
despite precautions taken at harvesting, there is always some
degree of endothelial loss induced by buffers, constriction,
dissection and mounting in culture plates. Because this
could vary between artery and vein, quantitating endothelial
loss should be essential. The evidence that the neutrophils
adhered to endothelial cells (and not subendothelium)
because less NO is released by SV compared with IMA was
that vessels pretreated with sodium nitroprusside or
L-arginine reversed the adhesion of neutrophils whereas
L-NAME enhanced it. However, the concentrations of the
agents used was very high (1–10 mM). Because these drugs
are taken up into the interstitial space of vessel segments,
they are probably released subsequently into the fluid
containing the neutrophils and therefore affect the neutro-
phils directly. For example, nitroprusside stimulates cyclic
GMP formation at 100 nM, which is 1/10,000th lower than
the concentration used by Chello et al. One way around
these above uncertainties would be to remove the endothe-
lium by rubbing and then to assess neutrophil adhesion
using the same treatments as for “intact” segments.
The overall question raised by this study is what role
endothelial NO plays in early or late vein graft failure. In a
study on porcine vein grafts, removal of the endothelium
result in early thrombotic occlusion (3) but had no effect on
neointima formation, supporting the idea that exposure of
the subendothelium, per se, and not endothelial NO for-
mation, is important in early thrombosis. In the same
model, endothelial NO synthase (eNOS) in SV grafts,
although initially low, is rapidly upregulated to similar levels
of arterial eNOS within one month (2).
Finally, it follows from the study of Chello et al. (1) that
the early administration of NO-donors may be beneficial in
obviating graft failure in CABG. However, this should be
approached with caution because NO elicits several poten-
tially dangerous effects, including apoptosis of endothelial
cells, promotion of VSMC proliferation and reactions with
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